Live
- 26/11 prosecutor to Mumbai North Central candidate - Ujjwal Nikam all set for 'new innings' with BJP
- CBI traces shop that sold bullets & cartridges seized from Sandeshkhali
- IPL 2024: Rasikh and Mukesh pick three-fers as Delhi Capitals beat Mumbai Indians by 10 runs
- 27 Indian startups secure over $222 million in funding this week
- Final Olympic qualifiers: India's Maheshwari leads the field heading into final day
- Govt allows export of 99,150 tonnes of onion to 6 countries
- KTR accuses Telangana CM of cheating people in phases
- IPL 2024: Samson elects to field as high-flying Rajasthan Royals take on Lucknow Super Giants
- Manikanta Gautam awarded honorary doctorate
- Shehzad Poonawala calls Arvind Kejriwal 'Pablo Escobar' who runs gang from jail
Zydus gets USFDA nod to market generic medication
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement. Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated. From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
